Skip to main content
TipRanks
Go Ultimate75% OFF

D.Western Therapeutics Institute (4576) AI Stock Analysis

2 Followers
JP:4576

D.Western Therapeutics Institute

(TSE/TYO:4576)

Select Model
Rating:38Underperform
Price Target:JPY 47.00â–²(0.00% Upside)
Action:reiterated
Date:11/07/26

The score is held down primarily by weak financial performance: the company remains deeply unprofitable with declining revenue and continued negative free cash flow, requiring ongoing external financing. Technicals compound the concern, with the stock trading below all major moving averages and negative MACD momentum, although extremely oversold RSI and Stochastic readings suggest the selling may be stretched. Valuation offers little support given negative earnings and no dividend. Offsetting positives include a materially stronger balance sheet, lower leverage at 0.42x debt-to-equity, high gross margins, and a meaningful halving of losses and cash burn versus 2024, which keeps the recovery case alive for risk-tolerant investors.

Positive Factors
Narrowing lossesLosses narrowed materially in 2025 versus 2024, showing some operating improvement despite continued unprofitability. If sustained, this trajectory could reduce the funding burden, improve capital efficiency, and move the drug-development platform closer to a viable earnings base.
Negative Factors
Persistent cash burnOperating and free cash flow were negative in every year shown, so operations have not yet funded themselves. Although 2025 burn improved materially versus 2024, continued negative FCF can require external financing and constrain investment in drug candidates over the next several quarters.

D.Western Therapeutics Institute (4576) vs. iShares MSCI Japan ETF (EWJ)

-60%-40%-20%0%20%40%JP:4576-52.53%EWJ+15.53%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
JPY 2.76B
Dividend Yield
―
Average Volume (3M)
352.70K
Price to Earnings (P/E)
-4.1
Beta (1Y)
0.03
Revenue Growth
-66.17%
EPS Growth
54.10%
Country
Japan
Employees
19
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

D.Western Therapeutics Institute Business Overview & Revenue Model

Company Description

D. Western Therapeutics Institute, Inc. is a biotechnology enterprise focused on the research, discovery, and innovation of various pharmaceutical drugs. The company's current portfolio includes GLANATEC and GLA-ALPHA, ophthalmic solutions prescribed...

D.Western Therapeutics Institute Financial Statement Overview

Summary

Financials reflect a development-stage biotech with deep unprofitability. The income statement (score 25) shows a ¥632 million net loss and a 7.9% revenue decline to ¥388 million, though losses halved versus 2024 and gross margin remains high at ~78%. Cash flow (score 28) is the weakest link, with ¥494 million of operating cash outflow and negative ¥497 million free cash flow, leaving the company reliant on external financing. The balance sheet (score 52) is the relative bright spot: equity nearly doubled to ¥1.44 billion and debt-to-equity improved to 0.42x from 1.09x. Overall, the improving loss and burn trajectory is encouraging, but there is no visible path to breakeven.

Income Statement

25Negative

Balance Sheet

52Neutral

Cash Flow

28Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue305.74M387.62M471.58M428.36M448.10M414.42M
Gross Profit251.40M301.24M424.74M391.70M420.53M394.32M
EBITDA-611.09M-572.35M-1.23B-775.59M-390.75M-110.03M
Net Income-651.85M-632.09M-1.29B-812.41M-429.69M-149.00M
Balance Sheet
Total Assets1.97B2.17B1.67B2.37B2.96B2.46B
Cash, Cash Equivalents and Short-Term Investments1.54B1.71B1.13B1.87B2.33B1.93B
Total Debt594.17M605.18M797.98M885.12M967.69M340.00M
Total Liabilities654.26M734.01M935.57M1.09B1.08B427.72M
Stockholders Equity1.31B1.44B733.87M1.28B1.86B2.01B
Cash Flow
Free Cash Flow0-496.54M-1.31B-601.76M-364.58M-179.21M
Operating Cash Flow0-493.79M-1.30B-586.82M-354.77M-176.31M
Investing Cash Flow0-2.45M-10.01M-15.25M-139.89M-111.15M
Financing Cash Flow01.08B567.63M134.47M867.30M-104.46M

D.Western Therapeutics Institute Technical Analysis

Technical Analysis SentimentNegative
Last Price47.00

Price Trends

50DMA67.22Negative
100DMA73.65Negative
200DMA82.05Negative

Market Momentum

MACD-5.89Positive
RSI21.42Positive
STOCH18.61Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4576, the sentiment is Negative. The current price of 47.00 is below the 20-day moving average (MA) of 55.60, below the 50-day MA of 67.22, and below the 200-day MA of 82.05, indicating a bearish trend. The MACD of -5.89 indicates Positive momentum. The RSI at 21.42 is Positive, neither overbought nor oversold. The STOCH value of 18.61 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4576.

D.Western Therapeutics Institute Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

JP:4576 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
JP:4978JP:497842NeutralJPY 11.33B-23.68――-8.23%-48.10%
JP:4592JP:459239UnderperformJPY 63.07B-16.39-37.79%――5.71%
JP:4576JP:457638UnderperformJPY 2.76B-4.06-47.54%―-66.17%54.10%
JP:4599JP:459938UnderperformJPY 7.90B-4.21―――4.85%
JP:4593JP:459337UnderperformJPY 27.92B-12.37――-51.55%52.19%
JP:7776JP:777637UnderperformJPY 6.11B-4.70――-49.43%-3.77%

* Healthcare Sector Average

Performance Comparison

-60%-40%-20%0%20%JP:4576JP:4592JP:4593JP:4599JP:4978JP:7776Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
JP:4576 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
JP:4576D.Western Therapeutics Institute, Inc.47.00-50.00-51.55%
JP:4592SanBio Co 808.00-1533.00-65.48%
JP:4593Healios KK206.00-280.00-57.61%
JP:4599StemRIM Inc.126.00-151.00-54.51%
JP:4978ReproCELL Inc.105.00-55.00-34.38%
JP:7776CellSeed Inc.154.00-225.00-59.37%

D.Western Therapeutics Institute Corporate Events

D. Western Therapeutics Outlines Q2 FY12/26 Results and Outlook

Aug 13, 2026

D. Western Therapeutics Institute has released briefing materials for its second quarter results for the fiscal year ending December 2026. The documents outline financial performance, progress in business activities, and an updated forecast for the f...

D.Western Therapeutics Posts Deeper Losses, Keeps 2026 Outlook Unchanged

Aug 13, 2026

D.Western Therapeutics Institute reported consolidated net sales of ¥33 million for the first half of 2026, an 80.9% year-on-year decline, with an operating loss of ¥312 million and a net loss attributable to owners of the parent of ¥323 million. Des...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 06, 2026